A*STAR

First made-in-Singapore cancer drug enters clinical testing

Thursday, July 23, 2015

A made-in-Singapore cancer drug has advanced into clinical trials, charting a milestone in Singapore’s biomedical sciences initiative that will go towards improving the lives of cancer patients in Singapore, and worldwide. The Agency for Science, Technology and Research (A*STAR) and Duke-National University of Singapore Graduate Medical School (Duke-NUS) have announced the start of a phase I clinical trial of novel cancer drug candidate, ETC-159.

[Read More]

Diagnostics Development Hub to boost biomedical research in Singapore

Thursday, December 4, 2014

Singapore’s biomedical research sector received a major boost with the launch of a new Diagnostics Development (DxD) Hub. The DxD Hub aims to develop medical diagnostics as one part of the medical technologies industry, improve healthcare through development of diagnostic solutions and accelerate production of new diagnostics devices. Diagnostics is one of four innovation clusters shortlisted to be funded under the $200 million Innovation Cluster Program (ICP) launched Oct. 2013.

[Read More]

Singapore’s influenza vaccines shows favorable immunogenicity, tolerability

Friday, January 31, 2014

Singapore’s Agency for Science, Technology and Research (A*STAR) and Switzerland’s Cytos Biotechnology have announced that their influenza vaccine (gH1-Qbeta) met its primary end point for immunogenicity (seroconversion based on haemaglutination inhibition titres according to FDA criteria) in the phase I clinical trial in healthy Asian volunteers. The induced immune response showed good cross-reactivity to recent drifted H1N1 strains. The H1N1 influenza vaccine candidate is based on Cytos’ proprietary bacteriophage Qbeta virus-like particle (VLP) technology.

[Read More]